A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 493
- 试验地点
- 29
- 主要终点
- Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog)
研究概览
简要总结
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD). According to the result of the phase II study, the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. So the study hypothesis is also that SaiLuoTong capsule will be effective in the treatment of patients with VaD and will be well tolerated. The purpose of the study is to confirm the efficacy and safety of SaiLuoTong capsule on patients with mild to moderate VaD. The outcome measures include general cognitive function, executive function, daily living skills, and mental behavior changes of symptoms in VaD patients.
详细描述
Vascular dementia (VaD) is a clinical syndrome of acquired intellectual and functional impairment that results from cerebrovascular diseases. SaiLuoTong capsule is a traditional Chinese medicine compound; it is composed of ginseng extract (the main composition: ginseng total saponins), ginkgo biloba extract (the main composition: YinXingTong ester) and safflower extract (the main composition: the west safflower total glycosides). The function of SaiLuoTong capsule is Yiqi Huoxue and Huayu Tongluo in Chinese traditional medicine theory. Pharmacodynamics studies showed that SaiLuoTong capsule can significantly improve neurological symptoms caused by focal cerebral ischemia in animals, and learning and memory ability in animal models of VaD. The result of the phase II study showed that the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. Based on these previous evidences, the investigators conduct this study to further confirm the efficacy and safety of SaiLuoTong capsule in patients with mild to moderate VaD. This study is a phase III clinical trial of SaiLuoTong capsule for treatment of vascular dementia. The study is a 52-week, multicentre, randomized, double -blind, placebo-controlled study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •40 years≤Age≤75 years, female or male.
- •With an education at more than (including) 6 years.
- •Meet the diagnostic criteria for dementia in Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-V).
- •Meet the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche etl'Enseignement en Neurosciences(NINDS-AIREN) Criteria of Probable Vascular Dementia (1993).
- •MRI (magnetic resonance imaging) supports the presence of ischemic cerebrovascular disease, and meets NINDS-AIREN Imaging Criteria; the diameter of each infarct≤ 30mm(And the perivascular spaces and cerebral microbleeds were excluded).
- •Modified Hachinski Ischemic (mHIS) Scale ≥
- •Hamilton depression scale (HAMD) ≤
- •Patients with mild or moderate VaD: 10 ≤ MMSE ≤ 26 and 1 ≤ CDR ≤
- •Willing to participate in this study and could sign the informed consent form by him/herself and lawful guardian prior to the study.
- •The subjects must have a care giver who are cognitively normal (MMSE scores: illiteracy> 17 points, 1 - 6 years of education > 20 points, 7 years and above of education > 24 points). The care giver shall also be able to take care of the patient at least 4 days a week for more than 4 hours a day while he or she can accompany the subjects to attend each visit. During the trial, a new caregiver must have MMSE score and the results would be presented in forms of subjects in the attachment.
排除标准
- •Patients with dementia caused by a brain disease other than VaD (such as Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease, central nervous system demyelinative diseases, tumour, hydrocephalus, trauma, central nervous system infection, such as syphilis, AIDS and Creutzfeldt-Jakob disease);
- •Patients with serious neurological impairment to finish the examination: hand hemiplegia, aphasia, and visual or hearing impairment.
- •Laboratory anomalies: hemoglobin (Hb) level less than 80g/L , platelet count (Plt) level less than 50×109/L, activated partial thromboplastin time (APTT) exceeds 2.5 times the normal upper level, fibrinogen(FIB) level less than 0.5g/L, prothrombin time (PT) exceeds 2.5 times the normal upper level, Serum creatinine (Scr) exceeds 3 times the normal upper level, alanine aminotransferase (ALT) exceed 5 times the normal upper level , aspartate aminotransferase (AST) exceed 5 times the normal upper level, alkaline phosphates (ALP) exceed 5 times the normal upper level , γ-glutamyl transferase (γ-GT) exceed 5 times the normal upper level, total bilirubin (TBiL) exceeds 3 times the normal upper level.
- •The subjects have nutritional and metabolic diseases and endocrine system diseases that cannot been controlled by therapy - thyroid diseases, parathyroid disease, vitamin or element deficiency.
- •Patients with serious circulatory system diseases, respiratory system diseases, urinary system diseases, digestive system diseases, haemopoietic system diseases (such as unstable angina, uncontrollable asthma and active gastrorrhagia) and cancer.
- •Serious mental disease (such as depression and schizophrenia) and epilepsy.
- •Gastrointestinal diseases that may affect the absorption, distribution, and metabolism of the investigational drug.
- •Alcohol and drug abuse.
- •Patients who have been given any drug that can affect the cognitive function (including Chinese herbal preparations containing any one of these: ginseng, ginkgo leaf, and saffron; Western medicines such as donepezil, karbalatine, rivastigmine, huperzine a, memantine and similar drugs, etc; Butylphthalide and other drugs with the same effect such as runeirergine, aniracetam, cytosporine, dihydroergine, nimodipine, etc) within one month before the start of this study and cannot be discontinued.
- •Patients who are allergic to more than 2 drugs or any component of the SLT capsules.
- •Pregnant or lactating women.
- •Patients who have participated in other clinical studies within 3 months prior to this study.
- •Cannot accept magnetic resonance imaging (MRI) examination.
研究组 & 干预措施
active group
take two pills (120 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
干预措施: SaiLuoTong capsule (Drug)
control group
take two pills (120 mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
干预措施: placebo (Drug)
结局指标
主要结局
Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog)
时间窗: Change from baseline VaDAS-cog score at Week 52
The VaDAS-cog comprises the Alzheimer's disease assessment scale(ADAS-cog) plus the Maze and Number Cancellation test to specifically assess executive function. The score of each item is summed to compute a total score. The range of the total score was from 0(no cognitive impairment) to 90(severe cognitive impairment). The data in the table below is the statistical data (mean,SD) of precise scores at screening and week 0 (baseline), while the statistical data of difference value compared to the score of Baseline at weeks 52.
Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC)
时间窗: Change from baseline ADCS-CGIC score at Week 52
The Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC) involves comparison of data acquisition from both home and clinic and the use of both informant-ratings and self-ratings. Important outcomes include clinical global impressions of change (CGIC) as indicators of clinically meaningful change. In week 0 (baseline), the score was to judge the severity of the cognitive, 0(no evaluate),1(normal),2(slight intelligence obstacle),3(mide intelligence obstacle),4(moderate intelligence obstacle),5(significantly intelligence obstacle),6(severe intelligence obstacle),7(intelligent obstacle end-stage). In week 13,26,39,52, the score was to judge the change of the clinical global impression,1(improved significantly),2(improve),3(improve a little),4(no change),5(a little deteriorated),6(deteriorated),7(serious deterioration).
次要结局
- Alzheimer's Disease Cooperative Study-activities of Daily Living(ADCS-ADL)(Change from baseline ADCS-ADL score at Week 52)
- Mini-mental State Examination(MMSE)(Change from baseline MMSE score at Week 52)
- Blood biomarker: Interleukin-6(IL-6)(Change from baseline MMP-9 at Week 52)
- Blood biomarker: Matrix metalloproteinase-9(MMP-9))(Change from baseline MMP-9 at Week 52)
- Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog)(Change from baseline VaDAS-cog score at week 39)
- Clinical Dementia Rating sum of boxes(CDR-sb)(Change from baseline CDR-sb score at Week 52)
- Clinical Dementia Rating(CDR Scale )(Change from baseline CDR Scale score at Week 52)
- Blood biomarker: Brain-derived neurotrophic factor(BDNF)(Change from baseline BDNF at Week 52)
- Blood biomarker: Vascular endothelial growth factor(VEGF)(Change from baseline VEGF at Week 52)
- Blood biomarker: Matrix metalloproteinase-9(MMP-9)(Change from baseline MMP-9 at Week 26)
- Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC)(Change from baseline ADCS-CGIC score at week 39)
- Alzheimer's Disease Cooperative Study-activities of Daily Living(ADCS-ADL)(Change from baseline ADCS-ADL score at Week 26)
- Mini-mental State Examination(MMSE)(Change from baseline MMSE score at Week 26)
- Clinical Dementia Rating(CDR Scale )(Change from baseline CDR Scale score at Week 26)
- Clinical Dementia Rating sum of boxes(CDR-sb)(Change from baseline CDR-sb score at Week 26)
- Blood biomarker: Brain-derived neurotrophic factor(BDNF)(Change from baseline BDNF at Week 26)
- Blood biomarker: Vascular endothelial growth factor(VEGF)(Change from baseline VEGF at Week 26)
- Blood biomarker: Interleukin-6(IL-6)(Change from baseline MMP-9 at Week 26)
- Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog)(Change from baseline VaDAS-cog score at week 13)
- Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog)(Change from baseline VaDAS-cog score at week 26)
- Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC)(Change from baseline ADCS-CGIC score at week 13)
- Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC)(Change from baseline ADCS-CGIC score at week 26)